Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early colchicine in high-risk older outpatients with COVID-19
2020-001603-16Phase 3Completed
- Sponsor
- IDIVAL
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by IDIVAL. Primary endpoint: Death or hospitalization due to COVID-19 within 30 days. Started May 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001603-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001603-16.